Peg-IFNα-2b

PreclinicalSmall molecule

IInstitute of Liver and Biliary Sciences, India

Peg-IFNα-2b is one of 84 small molecule programs targeting Chronic Hepatitis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic HepatitisActive, not recruiting

Combination TherapyRecruiting

Chronic HepatitisPreclinical

Active, not recruiting

Combination TherapyPreclinical

Recruiting

Competition

Competitive Landscape

71 competitors in Chronic Hepatitis

#DrugCompanyPhaseTrials

PEG-Intron

Merck & Co.

Phase 3

43 2

Actos

Takeda

Approved

3 3

Prograf

VVeloxis Pharmaceuticals

Approved

2 4

Glucophage

EMD Serono

Approved

1 5

PEGASYS

Ppharmaand GmbH

Approved

24 6

Opdivo

Bristol-Myers Squibb

Phase 2

2 7

Pegylated Interferon Alfa

Merck & Co.

Phase 3

4 8

NA Therapy

GSK

Phase 3

2 9

AHB-137

AAusper Biopharma Co., Ltd.

Phase 3

3 10

Hydronidone

BBeijing Continent Pharmaceutical Co, Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2032

Recruiting

Real-World Study

NCT07079150

Clinical

Trials by Indication[1]

PD-1antibody1 trial

The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB Patients

Active, not recruiting·—·N/A·NCT06357806·45 enrolled

Real-world Study1 trial

Real-world Study Evaluating the Long-term Outcomes of Pegylated Interferon α-2b Treatment in the Families With Clusters of HBV Infection and Unfavorable Prognosis - A Prospective, Controlled, Multicenter, Cohort Study

Recruiting·FFirst Affiliated Hospital Xi'an Jiaotong University··NCT07079150·1,500 enrolled

Chronic Hepatitis1 trial

To Study the Efficacy of PEG-IFN Alpha in HBeAg Negative Chronic Hepatitis B Patients After Stopping Nucleotide Analogue Therapy.

Unknown status·IInstitute of Liver and Biliary Sciences, India·N/A·NCT03123653·118 enrolled

HIV1 trial

Reducing Proviral HIV DNA With Interferon-a

Unknown status·TThe Wistar Institute·Phase 2·NCT02227277·54 enrolled

Combination Therapy1 trial

Sequential Combination Therapy With PD-1 Antibody and Peg-IFNα in CHB Patients

Recruiting·—·N/A·NCT06457477·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Peg-IFNα-2b. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Peg-IFNα-2b compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Peg-IFNα-2b. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Institute of Liver and Biliary Sciences, India company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: IInstitute of Liver and Biliary Sciences, India

Peg-IFNα-2b

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2032

Trials by Indication[1]

PD-1antibody1 trial

Real-world Study1 trial

Chronic Hepatitis1 trial

HIV1 trial

Combination Therapy1 trial

References

Drug Info

Quick Facts

Related News